Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Jiafen Gong¹, Gengming He^{1,2}, Cheng Wang¹, Claire Bartlett³, Naim Panjwani¹, Scott Mastromatteo¹, Fan Lin¹, Katherine Keenan^{1,3}, Julie Avolio³, Anat Halevy¹, Michelle Shaw³, Mohsen Esmaeili¹, Guillaume Côté-Maurais⁴, Damien Adam^{4,5}, Stéphanie Bégin⁴, Candice Bjornson⁶, Mark Chilvers⁷, Joe Reisman⁸, April Price⁹, Michael Parkins¹⁰, Richard Van Wylick¹¹, Yves Berthiaume⁵, Lara Bilodeau¹², Dimas Mateos-Corral¹³, Daniel Hughes¹³, Mary J. Smith¹⁴, Nancy Morrison¹⁵, Janna Brusky¹⁶, Elizabeth Tullis¹⁷, Anne L. Stephenson¹⁷, Bradley S. Quon¹⁸, Pearce Wilcox¹⁸, Winnie M. Leung¹⁹, Melinda Solomon²⁰, Lei Sun^{2,21}, Emmanuelle Brochiero^{4,5}, Theo J. Moraes^{3,20}, Tanja Gonska^{3,22}, Felix Ratjen^{3,23}, Johanna M. Rommens^{1,24}, Lisa J. Strug^{1,2,21,25, 26,*}

Affiliations:

¹Program in Genetics and Genome Biology, The Hospital for Sick Children; Toronto, ON, Canada.

²Biostatistics Division, Dalla Lana School of Public Health, University of Toronto; Toronto, ON, Canada.

³Program in Translational Medicine, The Hospital for Sick Children; Toronto, ON, Canada.

⁴Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.

⁵Department of Medicine, Faculty of Medicine, Université de Montréal; Montréal, QC, Canada.

⁶Alberta Children's Hospital; Calgary, AB, Canada.

- 22 ⁷ British Columbia Children’s Hospital; Vancouver, BC, Canada.
- 23 ⁸The Children’s Hospital of Eastern Ontario; Ottawa, ON, Canada.
- 24 ⁹ The Children’s Hospital, London Health Science Centre; London, ON, Canada.
- 25 ¹⁰ Foothills Medical Centre; Calgary, AB, Canada.
- 26 ¹¹ Kingston Health Sciences Centre; Kingston, ON, Canada.
- 27 ¹²Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec-
28 Université Laval; Québec City, QC, Canada.
- 29 ¹³IWK Health Centre; Halifax, NS, Canada.
- 30 ¹⁴ Faculty of Medicine, Memorial University of Newfoundland; St. John’s, NL, Canada.
- 31 ¹⁵Queen Elizabeth II Health Sciences Centre; Halifax, NS, Canada.
- 32 ¹⁶Jim Pattison Children’s Hospital; Saskatoon, SK, Canada.
- 33 ¹⁷St. Michael’s Hospital; Toronto, ON, Canada.
- 34 ¹⁸St. Paul’s Hospital; Vancouver, BC, Canada.
- 35 ¹⁹University of Alberta Hospital; Edmonton, AB, Canada.
- 36 ²⁰Respiratory Medicine, Hospital for Sick Children; Toronto, ON, Canada.
- 37 ²¹Department of Statistical Sciences, University of Toronto; Toronto, ON, Canada.
- 38 ²²Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children;
39 Toronto, ON, Canada.
- 40 ²³Department of Paediatrics, University of Toronto; Toronto, ON, Canada.

41 ²⁴Department of Molecular Genetics, University of Toronto; Toronto, ON, Canada.

42 ²⁵The Centre for Applied Genomics, Hospital for Sick Children; Toronto, ON, Canada.

43 ²⁶Department of Computer Science, University of Toronto; Toronto, ON, Canada.

44 *Corresponding author: Lisa J. Strug, PhD

45 Program in Genetics and Genome Biology

46 SickKids Research Institute

47 Room 12.9705, PGCRL

48 686 Bay Street

49 Toronto, ON

50 M5G 0A4

51 Email: lisa.strug@utoronto.ca

52 Tel: +1416-813-7654 X301762

53

54

55

Abstract

Background: Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator (*CFTR*) are CF-causing. *CFTR* modulators target variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing variants highlighting unmet needs. Alternative epithelial ion channel/transporters such as *SLC26A9* could compensate for *CFTR* dysfunction, providing therapeutic targets that may benefit all individuals with CF.

Method: We investigate the relationship between rs7512462, a marker of *SLC26A9* activity, and lung function pre- and post-treatment with *CFTR* modulators in Canadian and US CF cohorts, in the general population, and in those with chronic obstructive pulmonary disease (COPD).

Results: Rs7512462 CC genotype is associated with greater lung function in CF individuals with minimal function variants (for which there are currently no approved therapies; $p=0.008$); and for gating ($p=0.033$) and p.Phe508del/ p.Phe508del ($p=0.006$) genotypes upon treatment with *CFTR* modulators. In parallel, human nasal epithelia with CC and p.Phe508del/p.Phe508del after Ussing chamber analysis of a combination of approved and experimental modulator treatments show greater *CFTR* function ($p=0.0022$). Beyond CF, rs7512462 is associated with lung function in a meta-analysis of the UK Biobank and Spirometa Consortium (min $p=2.74 \times 10^{-44}$) and provides $p=0.0891$ in an analysis of COPD case-control status in the UK Biobank defined by spirometry.

Conclusion: These findings support *SLC26A9* as a therapeutic target to improve lung function for all people with CF and in individuals with other obstructive lung diseases.

Key words: *SLC26A9*, Cystic Fibrosis, *CFTR* modulator treatment, precision medicine, COPD

Background

Cystic Fibrosis [CF (MIM:219700)] is a common life-limiting autosomal recessive genetic disease caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR; MIM:602421). CF affects multiple organs; morbidity in the pancreas and intestine are seen at birth (1-3), while progressive lung disease is experienced throughout the course of disease and is the major cause of morbidity and mortality. Variability in disease severity across the affected organs is due, in part, to variation in other genes, referred to as modifier genes. Modifier genes impact phenotypic expressivity in the presence of a dysfunctional major causal gene, for example, *CFTR* (1, 4-7).

CFTR is localized to the cell membrane of epithelial cells and functions as an ion channel. Over 400 variants have been reported to cause CF through variable effects on protein function (<http://cftr2.org>; (8)). CF-causing mutations impact apical chloride and bicarbonate transport, altering hydration and pH of airway surface liquid resulting in viscous mucus. Accumulation of this viscous mucus leads to cycles of infection and inflammation, obstructing and damaging the airways, resulting in progressive lung damage and end-stage lung disease (9).

Developments in CF therapeutics over the past decade have been transformative, altering the management paradigm from treating the downstream consequences of dysfunctional CFTR and delaying the progression of the disease, to treating the basic defect in an individual's CFTR itself: *precision medicine*. New drugs enhance CFTR function by directly targeting the different defects in the protein. For example, individuals with gating mutations have access to a highly

effective modulator, ivacaftor (IVA), which is a potentiator that increases the opening probability of CFTR to aid chloride and bicarbonate ion transport in CF epithelia (10). The most common CF causing allele Phe508del (c.1521_1523delCTT; p.Phe508del) (11) displays minimal CFTR at the apical membrane due to processing defects (5, 6), and once at the cell surface the Phe508del protein exhibits reduced opening probability and stability. Pharmaceuticals targeting this defect include a combination therapy of IVA and a CFTR corrector lumacaftor (LUM) or tezacaftor (TEZ) that improves the Phe508del processing to increase cell surface localized protein as well as channel gating. More recently, a triple combination therapy of another corrector, elexacaftor, combined with tezacaftor and ivacaftor (ETI) has been approved in the United States (US) for individuals with at least one Phe508del aged 6 and above or other mutations responsive to Trikafta (<https://www.cff.org/Trials/Pipeline/details/10150/Elexacaftor-tezacaftor-ivacaftor-Trikafta>). Elexacaftor stabilizes the protein within the cell membrane, resulting in greater improvements in lung function over LUM/IVA or TEZ/IVA alone (12, 13). ETI is now indicated by the FDA for 90% of individuals with CF (<https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis>).

Although significant progress has been made in the development of pharmaceuticals for precision medicine in CF, several challenges remain. First, not all individuals with *CFTR* genotypes for which eligible pharmaceuticals are available respond to those treatments. Second, for those who do show a positive improvement in lung function, there is significant variability in the response (12-15), which could be augmented with additional therapies. Third, there are loss of function alleles that cannot be addressed using the current paradigm, and therefore an alternative approach to therapy beyond potentiators and correctors of CFTR is necessary.

Several alternative approaches are being actively pursued, including CFTR gene restoration and/or correction or alternative targets (9). Conceptually, alternative targets to CFTR aim to compensate for the abnormal dehydrated airway surface liquid that results from dysfunctional CFTR by modulating other ion channels, transporters and pumps (16-20) providing therapeutic options for those individuals with genotypes that do not produce CFTR protein and could assuage limited responses to existing CFTR modulators.

The clinical success rate of drugs in development is appreciably higher when there is human genetic evidence that supports a drug target (21). Genome-wide modifier gene studies in CF have aimed to identify genetic loci that impact disease severity in the presence of CFTR dysfunction in a hypothesis-free approach. First identified in a genome-wide association study (GWAS) of intestinal obstruction in CF (7), the C allele of rs7512462 in intron 5 of Solute Carrier Family 26 member 9 (*SLC26A9*) (chr1:205899595, hg19) has consistently demonstrated a beneficial effect for several CF co-morbidities, including in the exocrine (2, 3) and endocrine pancreas (4, 22). These co-morbidities appear to originate from pre-natal dysfunction in the CF pancreas (1, 3, 23). According to the Genotype Tissue Expression project (GTEx; (24) and <http://www.gtexportal.org/home/>), rs7512462 is an expression quantitative locus (eQTL) for *SLC26A9* where the C allele is associated with greater expression in the adult pancreas ($p=1.2 \times 10^{-5}$, effect size=0.27). Rs7512462 and additional *SLC26A9* eQTLs in the region of chr1: 205,806,897- 206,006,897(hg19) colocalize with the CF co-morbidity (meconium ileus) GWAS summary statistics (1), supporting gene expression variation is responsible for the observed CF GWAS finding.

Given the importance of attenuating progressive lung disease in CF, there was significant interest in investigating the contribution of *SLC26A9* to lung function despite a lack of association evidence with rs7512462 across a broad CF population, including the largest CF GWAS of lung function to date (5). *SLC26A9* is an anion chloride channel/transporter in epithelial cells that contributes to constitutive apical chloride conductance and enhances cAMP-regulated CFTR currents (25-28) and *Slc26a9*^{-/-}/*Cftr*^{-/-} mice show worse post weaning survival over *Cftr*^{-/-} models (29). Rs7512462 appears to associate with both the residual and activated current in lung cells (30, 31). In individuals with *CFTR* variants that maintain apical membrane localization, rs7512462 showed evidence of association with CF lung function (31) and the relationship was greatly enhanced upon treatment with the CFTR modulator IVA where the C allele was associated with greater lung function improvement (31, 32). That rs7512462 was not shown to be a strong modifier of CF lung disease (5, 31) in the absence of treatment with CFTR correctors but is associated with lung function in a non-CF population study (9, 33) is consistent with functional studies, where differential *SLC26A9* interaction with wild-type CFTR and with Phe508del-CFTR in human bronchial epithelia (HBE) has been reported (25, 31).

The functional and CF population studies highlight the potential of *SLC26A9* as a target to improve CF outcomes across the affected organs and to improve response to approved CFTR modulators. However, several questions remain including whether population studies support *SLC26A9* as providing alternative chloride transport in individuals with genotypes for which there are no approved therapies; whether enhancing *SLC26A9* will improve lung function response to CFTR modulators targeting the most common Phe508del variant; which patient-

specific cell-based models of the airway demonstrate SLC26A9 expression; and whether enhancing SLC26A9 could benefit other obstructive lung diseases such as chronic obstructive pulmonary disease (COPD) in light of the rs7512462 association with lung function in non-CF population studies (33).

Through continued recruitment into the Canadian CF Gene Modifier Study (CGMS) and in collaboration with the US PROSPECT observational study ((34); <https://clinicaltrials.gov/ct2/show/NCT02477319>), we investigate the association between rs7512462 and (1) lung function in individuals with CF with different *CFTR* genotypes including variants that result in no CFTR protein product (i.e. minimal function alleles); (2) individual lung function responses to CFTR modulators IVA and LUM/IVA; (3) CFTR function in primary cultured human nasal epithelia (HNE) from individuals with CF in response to approved and experimental CFTR modulators; and (4) other phenotypes in non-CF populations to inform the clinical utility of SLC26A9 modulators beyond applications in CF.

Methods

Study Design

The Canadian Cystic Fibrosis Gene Modifier Study (CGMS) is a registry-based observational genetics study. The US Part B Cystic Fibrosis Foundation (CFF) Therapeutics PROSPECT study is an observational study of modulator treatment. The current study investigates the relationship between rs7512462 and lung function pre- and post-CFTR modulators in Canadian and US CF cohorts; in the general population; and in a case control study of chronic obstructive pulmonary disease (COPD).

Clinical data collected as part of the CGMS include forced expiratory volume in 1 second (FEV₁), age, sex, and height which are all obtained from the Canadian CF Patient Data Registry (CCFRD), with occasional augmentation by chart review at the participating sites. Genetic data is linked to clinical data through an approved data access agreement with Cystic Fibrosis Canada. Part B of the CFF Therapeutics PROSPECT observational study (<https://clinicaltrials.gov/ct2/show/NCT02477319> and (34)) in the US evaluated the effectiveness of LUM/IVA and collected buffy coat and clinical data from individuals with two copies of the Phe508del variant who were prescribed LUM/IVA. We received the PROSPECT study buffy coat and corresponding clinical data from the US CFF. DNA was extracted for genotyping on Illumina platforms as described in Supplementary Information for sample genotyping and quality control.

Phenotypes, Sampling and Inclusion Criteria

The CGMS has enrolled 3,257 participants from 9 provinces and 35 clinics across Canada with a range of *CFTR* genotypes that are reflective of the Canadian CF population. To investigate the association of *rs7512462* with pre-treatment lung function, we specifically study the subgroups of the CGMS who are: (1) homozygous for Phe508del; (2) carrying at least one copy of the G551D (c.1652G>A;p.Gly551Asp) variant or another gating variant approved for IVA; and (3) individuals with two *in trans* minimal function (MF) variants (<https://www.cff.org/research-clinical-trials/types-cftr-mutations>) for which there are no CFTR modulators approved; these include nonsense, splicing and small indel variants that cannot be targeted by CFTR modulators (Fig. 1). Lung function severity in the absence of modulator treatment for participants in CGMS

was measured by Saknorm, the survival adjusted average CF-specific Kulich FEV₁ percentiles that is normalized (5, 31, 35). For participants whose recruitment year was after 2008, Saknorm is calculated using Canadian CF-specific reference equations from 2008–2014 (36), rather than US reference equations (37). Saknorm enables comparison of CF lung disease across the age spectrum where there is differential mortality and is therefore used as a phenotype in CF genetic association studies. After quality control (QC), n=89 participants with at least one gating mutation, n=1,266 with homozygosity for Phe508del and n=63 with two MF alleles in trans are included in the analysis. Of these participants, 54 individuals with at least one gating mutation and 1,013 who are homozygous for Phe508del were also included in a previous publication (31) (Fig. 1).

CGMS participants prescribed IVA or LUM/IVA were also included in the treatment response study, together with the US PROSPECT participants for LUM/IVA (Fig. 1, Table 1). Participants from the PROSPECT study were younger and healthier than the Canadian cohort (as measured by forced expiratory volume in one second (FEV₁) percent predicted (FEV_{1pp})) at treatment initiation (Table 1). Similar to (31), all participants included for modulator lung response analysis had a baseline measurement between 30 and 96 FEV_{1pp} measured within 3 months prior to, or on, the treatment initiation date. The CGMS data is obtained from the CCFRD with variable longitudinal entry depending on the resources of the individual clinics across the country while PROSPECT collected regular measurements at 1, 3, 6 and 12 months after treatment initiation. To account for this difference, the LUM/IVA treatment response is defined as the difference in FEV_{1pp} between the first visit on treatment within 5-7 months and

that measured at baseline following convention in the literature (38); for the IVA study, aligned with reported treatment responses seen by 15 days (10), the difference between mean FEV_{1pp} within 15 to 400 days to FEV_{1pp} baseline (31), as well as the difference between the longitudinal FEV_{1pp} within 15 to 400 days to FEV_{1pp} baseline are used. We also investigated an IVA analysis with treatment response defined as the difference from the 1st FEV_{1pp} within 15 to 60 days after the treatment initiation; the conclusion is comparable but because the sample size is reduced to 33, we report the mean treatment response and longitudinal treatment response in 15 to 400 days. After phenotype and genotype QC, 91 participants from PROSPECT and 104 CGMS participants were included in the genetic analysis for LUM/IVA and 45 for the IVA study (see Supplementary Table 1 for sample exclusion; Fig. 1).

We also investigated CFTR function in 46 CF Canada SickKids Program in CF Individualized Therapy (CFIT; (39)) participants homozygous for Phe508del whose nasal epithelia were brushed, cultured to passage 2 (P2) and mounted in a circulating Ussing chamber. Thirty-six individuals who underwent brushing prior to modulator initiation and for whom we had rs7512462 genotype are included in the Ussing chamber analysis (Supplementary Information for additional cell culture and Ussing chamber study information; Fig. 1).

A subset of the CGMS cohort (n=82; Fig. 1) and 6 healthy controls had RNA from their nasal cells sequenced as part of CFIT. In addition, we have sequenced nasal cells for 9 CFIT samples cultured to passage 3 (P3) at two time points (14-16 days and 26-30 days). We also sequenced the RNA from de-identified CF individuals who underwent lung transplantation, obtained from paired human bronchial and nasal epithelia; n=17 independent pairs of uncultured primary HNE

and HBE and n=16 cultured HNE and HBE pairs (Supplementary Information for sampling and cell culturing).

Illumina Smart-Seq2 single-cell RNA data from three individuals were obtained from the Human Lung Cell Atlas (40). The donors consisted of two males and one female, aged between 46 to 75 years. The samples were freshly resected lung tissues obtained during surgery with confirmed normal histology (except for very mild emphysema in some of the samples from one individual).

Summary association statistics from other GWAS phenotypes were obtained from the GWAS ATLAS (41) (Supplementary Information for PheWAS data extraction). Association between rs7512462 and lung function was assessed using the UK Biobank data under application #40946, or was investigated using summary statistics from (33) when available.

Association Analysis of rs7512462

i. Association with lung function (Saknorm) by CFTR genotype group

To assess whether rs7512462 was associated with Saknorm in the different *CFTR* genotype groups, we carried out a stratified analysis, separately for those with gating variants (or the subset specifically with G551D), those homozygous for Phe508del and those with two minimal function (MF) variants, using both additive and recessive models. In each *CFTR* genotype subgroup, the association analysis used the R package ‘rms’ (42) to obtain a robust variance estimator and the linear regression included an indicator for which reference cohort was used to calculate the Saknorm phenotype. For individuals with at least one G551D variant, the rs7512462 association in CGMS is meta-combined with that from four previously published

cohorts: a cohort from France (32) and 3 from the United States (43). For CF individuals homozygous for Phe508del or for those with at least one gating mutation, the rs7512462 association results are also meta-combined with those reported in (32). Meta-analysis is implemented using inverse variance and sample size weighting with the R functions ‘metagen’ in the package ‘meta’ (44) and ‘rma’ in the package ‘metafor’ (45), respectively and the R package ‘forestplot’ is used to generate forest plots (46). To assess whether lung function is different between the three *CFTR* genotype groups, we regressed Saknorm on two indicators for the three *CFTR* genotype categories. Additionally, to assess whether the effects of rs7512462 genotype on Saknorm were different between the three *CFTR* genotype groups, we included an SNP-*CFTR* interaction term in the regression model and performed an F-test using the aov function. All analyses adjusted for the reference cohort used to calculate Saknorm and only two-sided p-values less than 0.05, and with the direction that the C alleles is beneficial, are considered significant.

ii. Association with response to modulator treatment

We also use multivariable regression with robust variance estimation to assess the association of rs7512462 with the modulator FEV_{1pp} response, where rs7512462 is coded recessively to align with what is observed in exploratory data analysis (Fig. 2). For the association with treatment response to IVA, covariates include age and FEV_{1pp} at baseline. To account for the variable follow-up days and the variable baseline measure time prior to the treatment initiation, we also implement a linear mixed-effect model for participants on IVA and with follow-up measurements between 15 to 400 days using the R function ‘lmer’ in the package ‘lme4’ with a random intercept (47).

For treatment response to LUM/IVA, besides rs7512462, age and FEV_{1pp} at baseline, principal components (PCs) were also included to adjust for population structure, which were calculated from the PROSPECT or the combined CGMS and PROSPECT studies by the R function PC-AiR in the GENESIS package (48, 49) using the kinship matrix estimated by KING 2.2.4 (50). The significant PCs were selected based on the Tracy-Widom test using the function twtable in POPGEN of Eigensoft (51) ; 7 PCs were included for the US PROSPECT analysis and 4 PCs for the US PROSPECT+CGMS combined analysis. Analysis of the Ussing chamber data to assess association of CFTR functional response to CFTR modulators with rs7512462 uses multivariable regression with a robust variance estimator, adjusted for a binary indicator of culture media. The boxplots are obtained using the functions ggplot and geom_boxplot from the package ggplot2 in R (52) and the function geom_jitter from ggplot2 is used to overlay the individual measurements in a stripchart.

iii. Association analysis with COPD and non-CF lung function in the UK Biobank and SpiroMeta Consortium

Genetic association analyses for spirometry measures in the UK Biobank were conducted using imputed (v3) phenotypic data obtained from the UK Biobank (53, 54). In-house scripts, R package rbgen and C++ tool bgenix (55), were used to index, subset and perform association analysis using imputed dosage (53). COPD was defined according to the GOLD (levels 2 to 4) criteria of moderate to very severe airflow limitation (56) (FEV₁/FVC ratio < 0.7 and FEV_{1pp} < 80%). Prior to analysis, spirometry and genotyping quality control (QC) were carried out as suggested in (33), with the exception of kinship and ethnicity analyses, where we opted to use KING's (v.2.0) --unrelated option (50) and the UKBB's UID 22006 for the identification of

Europeans. This QC method is more conservative and yielded 263,461 participants compared to 321,047 participants in (33). We removed individuals with incomplete data for sex (UID=22001), age (UID=21022), height (UID=50), and smoking status (ever/never, UID=20160). FEV_{1pp} was calculated using the Global Lungs Initiative (GLI) calculator using the best FEV₁, age (UID=21022), height (UID=50), and sex (UID=22001). From these, 22,071 participants fit the spirometrically-defined COPD criteria. Summary statistics for population-level GWAS of spirometry (FEV₁/FVC ratio, and peak expiratory flow (PEF)) were obtained from meta-analysis of the UKBB and SpiroMeta Consortium (33). Phenotypic analysis at the *SLC26A9* locus included the best measures for PEF, FEV_{1pp} and FEV₁/FVC ratio. The best measure for FEV₁ (UID=20150) and FVC (UID=20151) were defined as the highest measure from the array of values of up to three blows (UID=3063 and 3062, respectively) that were deemed acceptable according to blow quality metrics (UID=20031): “blank”, “ACCEPT”, “BELOW6SEC ACCEPT” and “BELOW6SEC”; and a back-extrapolated volume (derived from the blow curve time series, UID=3066) greater than 5% or less than 150mL, as explained in (33). The best FEV₁/FVC is calculated from the selected best FEV₁ and FVC after determining blow reproducibility within 250mL from any other blow as explained in (33). Principal components were calculated using flashPCA2 v2.1 (57) which is designed for Biobank-scale data. All association models included three principal components, sex, age, age², sex × age, sex × age² and smoking (ever/never). All spirometry measures were inverse rank normal transformed prior to association analysis using the RNOmni R package’s (v0.7.1) rankNorm function (58). Association summary statistics from each of the lung function phenotypes were then used for colocalization analysis in LocusFocus (v1.4.9; (59)).

Haplotype analysis of CGMS in CF participants homozygous for Phe508del

Risk haplotypes that include rs7512462 were reported to associate with age-of-onset of CF-related diabetes in individuals homozygous for Phe508del (60) and here we similarly construct these haplotypes and assess their association with Saknorm. Lam et al (60) constructed the haplotypes from 41 common SNPs (MAF>15%) in the same linkage disequilibrium (LD) block as rs7512462 and found that two common haplotypes are associated with later CFRD onset (low risk (LR), minor haplotype frequency [MHF]=28.4%, $p=1.14 \times 10^{-3}$) and earlier CFRD onset (high risk (HR), MHF=24.1%, $p=4.34 \times 10^{-3}$) (n=594) when using PLINK's haplotype analysis command (--chap and --each-vs-others).

To mimic this haplotype analysis we used imputed genotype data from the CGMS (1) in individuals homozygous for Phe508del (n=1,266). The imputed data included 40 of the 41 variants used by Lam et al (60), with the multi-allelic variant rs144469431 removed. A subset of n = 447 CGMS participants sequenced using 10X Genomics linked-read whole genome sequencing technology (10XG, Supplementary Information), which facilitates improved phasing, was used as the reference panel to phase these imputed data into haplotypes. We then implemented two analyses. The first analysis used the same PLINK command as in (60) in an unrelated set of CGMS Phe508del/Phe508del participants (n=1,164). The second analysis is in a larger subset that includes related individuals and conducts haplotype association using linear regression with a robust variance estimate that accounts for the relatedness (n=1,266), comparing each of the eight haplotypes studied in (60) to a comparison group that includes all others using an additive model.

RNA Sequencing, Quality Control and analysis

The CF human nasal epithelia (HNE) cells were sequenced on the Illumina HiSeq 2500 platform (Illumina Inc. San Diego, California, USA) and aligned as described in (39). Expression counts were quantified using RNA-SeQC (ver. 2.0.0) and normalized to transcripts per million (TPM) (61) as well as trimmed mean of M values (TMM) measures (62) .

To compare the expression level for *SLC26A9* across the different airway models, we calculated the TPM from naïve HNE for 82 CGMS participants and 6 healthy controls, 16 pairs of de-identified cultured HNE and HBE, 17 pairs of de-identified naïve HNE and HBE and 9 CFIT cultured HNE samples.

eQTLs were calculated from 79 CGMS participants for whom both genotype and RNA sequence from naïve HNEs were available (Fig 1). Quality control required TPM ≥ 0.1 and read counts ≥ 6 in greater than 20% of the sample to be analyzed. FastQTL (ver. 2.0) was used to conduct differential gene expression analysis of TMM-normalized read counts on SNP genotypes (63). Covariates included the top 3 genotype principal components, 15 probabilistic estimation of expression residual (PEER) factors, sample study source, sex, genotyping platform, RNA integrity number (RIN) and PTPRC/CD45 gene expression which adjusts for immune cell composition in the samples. The genotype principal components and PEER factors were generated using R packages GENESIS (48, 49) and peer (64), respectively. The average expression level of *SLC26A9* was compared across HBE and HNE in both cultured and naïve paired tissues. Paired t-tests were conducted using the *t.test()* function in R v3.6.1 (65), based on TPM.

For the Human Lung Atlas single cell data (40), cellular expression profiles were clustered by nearest-neighbor for visualization. RNA count data and cell annotations provided in this dataset were used; counts were normalized (library-size corrected) to 1,000,000 reads per cell and log-scaled. Scanpy v1.8.2 in Python 3.7 was used for the *CFTR* and *SLC26A9* single-cell expression visualization of the Human Lung Cell Atlas data (66).

A subset of these samples with expression from more than 500 genes and greater than 50,000 total mapped reads were used for statistical modeling of *CFTR*-*SLC26A9* co-expression. Library sizes were normalized using the TMM method. Log-transformed read counts per million (log-CPMs) were generated using the normalized library sizes and were used to calculate the Spearman's correlation between the *CFTR* and the *SLC26A9* genes. Expression raw read count from *CFTR* was regressed on that of *SLC26A9* in the zero-inflated negative binomial model analysis with a log link function. Normalized library size was adjusted using an offset term. Zero-inflation was modelled by the detection rate variable which is the proportion of genes with expression data in a cell. The effect size estimate indicates log-ratio relations between *CFTR* and *SLC26A9* expression. The Spearman's correlation and the zero-inflated negative binomial model analysis were performed by R function `cor.test()` and package `pscl` (67), respectively.

Results

rs7512462 is associated with CF lung function in the absence of treatment measured as Saknorm

Using the International CF Gene Modifier consortium lung phenotype, Saknorm ((35); Methods), we compared lung function across the three *CFTR* genotype groups. Saknorm

measures differ significantly between individuals with a gating variant (n=89) versus those who are homozygous for Phe508del (n= 1,266; effect size=0.20, p=0.030), while individuals with two MF variants (n=63) do not differ in Saknorm from Phe508del homozygotes (effect size= -0.11, p=0.27).

In CGMS participants with at least one G551D variant (n=79), rs7512462 did not reach statistical significance at the 0.05 level with Saknorm (effect size = 0.185, p=0.225). Meta-combining the CGMS association evidence with association results from four independent cohorts, a cohort from the French gene modifier study (FGS) with n=49 participants (32) and three cohorts with n=272 participants reported in Eastman et al (43), results in an effect size of 0.11 with p=0.05 and an effect size=0.12 with p=0.036 from inverse variance weighted and from sample size weighted meta-analyses, respectively (Fig. S1; Supplementary Table 2). Meta-analysis of rs7512462 Saknorm association from the FGS (32) and CGMS cohorts with at least one gating variant approved for ivacaftor have similar but more variable effect size than that from the G551D subset (effect size =0.12 with p=0.18; Supplementary Table 2).

In individuals from the CGMS who are homozygous Phe508del (n=1,266), each C allele is associated with an increase in lung function, albeit with a smaller effect size (effect size = 0.069, p=0.028, Fig. 2a; Fig. S2). Meta-analysis of this CGMS association with an rs7512462 Saknorm association in n=1,802 individuals who are Phe508del/Phe508del from the FGS (32) also show association in both inverse variance weighted (effect size=0.050, p=0.021) and sample size weighted (effect size=0.046, p=0.037) meta-analyses (Fig. S2; Supplementary Table 2). Constructing haplotypes in the CGMS in individuals homozygous for Phe508del as in (60) does

not provide evidence for significant low risk (LR) or high risk (HR) haplotypes contributing to Saknorm variation (Supplementary Table 3) and does not provide greater power than using the single SNP rs7512462 to mark the locus for association with lung function (Supplementary Result; Supplementary Table 3).

Importantly, in individuals with two MF variants, the CC genotype is associated with improved lung function when compared to individuals with the TT and TC genotype (effect size=0.45, $p=0.0083$, Fig. 2a). This is consistent with the hypothesis that for rs7512462 marking SLC26A9 activity, SLC26A9 may be providing alternative chloride transport properties in individuals with *CFTR* variants for whom no current approved therapies exist.

When combining CGMS participants from the three genotype groups in a joint multivariable regression model to assess the association with rs7512462, the C allele is associated with greater lung function ($p=0.017$ and 0.022 for additive and recessive models, respectively, Table 2). Fitting an interaction term in this multivariable model, the C allele does not demonstrate a statistically significant difference in effect size depending on one's *CFTR* genotype (interaction p -values 0.90 and 0.46 for additive and recessive models, respectively).

Rs7512462 C allele is associated with improved response to CFTR modulators

Newly recruited participants into the CGMS on IVA ($n=23$) were, on average, older and had worse baseline lung function than those included in (31) (Table 1). Despite the difference in baseline characteristics and disease severity, we do observe additional supportive evidence for improved lung function response when combining the newly and previously recruited participants (difference in FEV_{1pp} pre and post treatment initiation) in individuals with the CC

genotype upon treatment with IVA (effect size=9.9, $p=0.03$, Table 3; Fig. 2b). Results from a linear mixed-effect model which accounts for the longitudinal nature of the data provides consistent results (effect size =12.76, $p=0.025$; Supplementary Table 4).

Through ongoing recruitment in the CGMS there were 104 participants prescribed LUM/IVA clinically. In collaboration with the US PROSPECT observational study, we investigated lung function response to LUM/IVA alone ($n=91$) and in a combined sample of $n=195$ individuals homozygous for Phe508del stratified by rs7512462. Despite minimal clinical response to LUM/IVA reported on average (14), we do observe a significant improvement in lung function response in those with the CC genotype ($p=0.002$ in US PROSPECT and $p=0.006$ for combined, respectively; Table 3), akin to observations for IVA (Fig. 2b and (31)), and in studies of improved CFTR function with the rs7512462 C allele in HNE (30) and HBE (18, 31) cells obtained from individuals homozygous for Phe508del. Thus, the rs7512462 genotype shows improved response to the LUM/IVA combination therapy in cohorts of CF patients who were monitored observationally during their real-world experience with the approved modulators.

We investigated CFTR-mediated current in 36 cultured HNE from CGMS participants homozygous for Phe508del upon treatment with VX-770+VX-809 (as in (30), corresponding to the IVA/LUM combination; VX-770 applied acutely) and upon treatment with VX-770+VX-809 + an amplifier under experimental investigation ((68); Fig. 3). We used the HNE from the earliest passage available to us (P2) to align with (30). Defining the treatment response as the difference in ΔI_{eq} -forskolin from DMSO to VX-770+ VX809 ($n=36$) or VX-770+ VX-809 + amplifier ($n=30$), we see a significant improvement in CFTR function in the CC group (effect

size=-1.934, $p=0.0022$, Table 4) in HNE with VX-770+VX-809+ amplifier. The increase in CFTR function in the CC group in the cultured HNE with VX-809 does not reach statistical significance (effect size=-0.406, $p=0.338$, Table 4) unlike previous reports in HNE and in HBE models, although the direction of effect is consistent. This difference in effect size made us question the *SLC26A9* gene expression profile across different lung tissue models, especially given the low passage of the primary HNE cultured cells studied by (30).

SLC26A9 expression differs across airway models

While investigating eQTLs in various airway tissue models, we observed that there is no evidence supporting rs7512462 as an eQTL in the lungs from GTEx v8 ($p=0.71$) or from RNA obtained from naïve HNE of individuals with CF ($p=0.64$, $n=79$) despite its association with residual and activated current in Ussing chamber studies (30, 31). *SLC26A9* expression appears generally low across several different lung model systems we investigated, with an average of 1.34 transcripts per million (TPM) (Fig. S3a). We generated a resource that contains the transcriptomes from paired cultured and fresh naïve HNE and HBE tissue on the same individuals (Methods; GEO ID: GSE172232)). Of the primary lung cell models we investigated, the greatest expression is in the naïve HBE cells (TPM=1.94; Fig. S3a), and this expression level is 2.1-fold greater than in the naïve HNE ($p=0.04$, paired analysis in $n=17$ HNE-HBE naïve pairs). Unfortunately, naïve HBE cell models are not generally accessible for personalized medicine approaches (39), and cultured models are the norm. Here cultured HBE show mean expression with TPM=1.71 that is 2.5-fold greater than the CF cultured HNE ($p=0.02$, paired analysis for $n=16$ HNE-HBE cultured pairs), although there is some indication that a reduction in culturing time results in greater *SLC26A9* expression in the HNE (Fig. S3b).

Using single-cell RNA-seq data catalogued in the Human Lung Cell Atlas (40), we investigated the expression of *SLC26A9* and *CFTR* across cell types. Within lung cells, both genes are expressed in the epithelial cells of the alveoli and airway, particularly within alveolar type 2 (AT2) cells and club cells (Fig. 4). These cell types are also supported by single-cell Human Protein Atlas data ((69); <http://www.proteinatlas.org/>), which reports expression in AT2 cells (normalized TPM of 50.1 for *SLC26A9* and 65.6 for *CFTR*) and club cells (normalized TPM of 2.7 for *SLC26A9* and 17.8 for *CFTR*). Furthermore, single-cell GTEx data ((70, 71); <http://www.gtexportal.org/home>) shows concordant evidence where, *SLC26A9* and *CFTR* reads are observed in an appreciable fraction of AT2 cells (24.59% *CFTR*, 12.41% *SLC26A9*) and club cells (28.79% *CFTR*, 5.45% *SLC26A9*).

We assessed the evidence for *CFTR*-*SLC26A9* co-expression among the club, basal and alveolar epithelial cell types identified in the Human Lung Atlas study (40). Both the Spearman's correlation and the zero-inflated negative binomial model indicated significant association between the *CFTR* and the *SLC26A9* read counts for AT2 cells (Table 5). The model estimate suggests positive co-expression between the two genes (log ratio = 0.00035, p=0.00974).

Phenome-wide Association Study (PheWAS) of rs7512462 and colocalization analysis

We used the GWAS ATLAS database (41) that includes 4,756 GWAS from 473 unique studies with 3,302 unique traits, and the UK Biobank resource to investigate other non-CF traits associated with rs7512462. The 10 traits with the smallest reported p-values are listed in Table 6, four of which are respiratory phenotypes from the UK Biobank and Spirometa consortium (33):

PEF and FEV₁/FVC ratio. Saknorm, the lung function measurement used in the CF GWAS, is also calculated from FEV₁ (5, 35). The list of significant phenotypes also includes our own CF modifier gene study where we first identified rs7512462 as a modifier of intestinal obstruction at birth, meconium ileus with evidence of an exocrine pancreatic origin ((1); Table 6). Interestingly, an earlier age at menarche (which is associated with weight) and a higher male waist circumference and waist-hip ratio are also associated with the rs7512462 C allele. The association of rs7512462 with type 1 diabetes and the weight-related phenotypes suggest that the role in these reproductive and metabolic phenotypes may likewise trace back to an exocrine pancreatic origin. Significant colocalization analysis (column 'Colocalization P-value', Table 6) calculated using the Simple Sum (1, 72) implemented in LocusFocus (59) between the meconium ileus CF GWAS statistics (1) and the summary statistics from the PheWAS associated traits supports that the same genetic variation contributes to the traits.

Airflow limitation is a key diagnostic feature of COPD (73). In the UK Biobank we analyzed n=22,071 of 263,461 participants with moderate to severe airflow limitation defined by the Global Initiative for Obstructive Lung Disease (GOLD) criteria (56). Although rs7512462 is a modifier of PEF and FEV₁/FVC ($p=2.74 \times 10^{-44}$ and $p=4.11 \times 10^{-5}$, respectively) from ((33); Table 6), the evidence is not as conclusive for FEV₁pp and COPD case control status in UK Biobank ($p=0.56$, 0.0891 , respectively; Fig. 5).

Discussion

The availability of CFTR modulators is altering care for many individuals with CF, although variation in responses are apparent, partially due to individual genetic backgrounds. One such

genetic factor is *SLC26A9*, which contributes to early onset CF comorbidities in the pancreas and intestine (1, 4, 22, 60). Unlike for these early-onset phenotypes where the rs7512462 SNP is a *SLC26A9* eQTL in the pancreas and *SLC26A9* and *CFTR* appear to contribute to these phenotypes independently (1, 7, 31), in the lungs the mechanism that is being marked by rs7512462 is not immediately obvious from the genetic data. Meanwhile, some have also questioned whether rs7512462 is even associated with lung function (43).

To address the connection between rs7512462 and *SLC26A9*, we integrate evidence from population and functional studies. The rs7512462 SNP was shown to associate with lung function or lung response to *CFTR*-modulators in individuals that carry *CFTR* variants that result in apical membrane localization for *CFTR* (31) and this is further supported here. Although rs7512462 does not show eQTL evidence based on lung tissue expression, *SLC26A9* is present in HBEs (28, 74, 75) and Fig. S3 and Larsen *et al* (28) show that *SLC26A9* is a major contributor to constitutive anion secretion across HBEs. In (31) Figure 3B prior to *CFTR* correction in Phe508del/Phe508del HBE monolayers, rs7512462 shows evidence of association with residual forskolin stimulated current ($P = 0.09$, $-0.17 \mu\text{A}/\text{cm}^2 \Delta I_{\text{eq-forskolin}}$ per C protective allele) in Ussing chamber studies. A relation between rs7512462 genotype and transepithelial current in uncorrected Phe508del *CFTR* was also shown by others in HNE cultures with Phe508del *CFTR* genotypes (30).

Experimental evidence for a relationship between the rs7512462 genotype and *CFTR* function in airway cell models and here in CF participant responses was also observed by rescuing the traffic-defective Phe508del with corrector modulators (30, 31). Published in vitro and cell studies

have demonstrated a CFTR-SLC26A9 interaction in lung cells and together with recent work by ((28, 74, 75) and references within), evidence is emerging that SLC26A9 may also stabilize CFTR. Therefore, we interpret that the contribution of SLC26A9 that rs7512462 is marking for lung phenotypes may be from both anion channel activity and enhancement of apical membrane bound CFTR.

To address the uncertainty in evidence for *rs7512462* association with lung function (43), here we extend several genetic association studies. We investigate the role of *rs7512462* genotype in CF patients with different types of CFTR mutations and in treatment response to CFTR modulators both in patient populations and in airway models. We align the findings and previously published work with gene expression patterns including understanding of cell type specific *SLC26A9* and *CFTR* co-expression, and now also consider the role of rs751242 in the phenome and, in particular, in lung function measurements in non-CF populations. Significant human genetic evidence that supports a role for *SLC26A9* in CF disease severity and CFTR modulator response is accumulating. Here we provide the most comprehensive investigation of the role of rs7512462 as a marker of *SLC26A9* activity in CF and non-CF populations.

The relationship between the *SLC26A9* rs7512462 marker and lung function in three types of *CFTR* genotypes was revealing. Individuals with the CF-causing G551D gating variant show association with rs7512462. Gating-deficient CFTR protein exhibits epithelial apical cell membrane localization with reduced opening probability, resulting in reduced epithelial chloride and bicarbonate secretion characteristic of CF (76). In contrast, individuals homozygous for Phe508del, comprising the majority of CF cases, show more modest evidence of

association with rs7512462. Phe508del-CFTR is rapidly degraded intracellularly with minimal surface membrane localization. Meanwhile, for the first time, we demonstrated that individuals with MF variants do show rs7512462 association but with absence of CFTR protein cannot respond to CFTR modulator therapy. The studies of MF alleles support that at least some aspect of lung function contribution by SLC26A9 can be independent of CFTR. These investigations align with several previous studies highlighting the potential for SLC26A9 to provide (alternative) chloride transport that functions independently of CFTR (25, 26).

CF GWAS of early-onset CF pancreatic and intestinal phenotypes were CFTR genotype *independent* (1-3, 7); that is, those homozygous for Phe508del still demonstrated genome-wide significance with benefit from the C allele of rs7512462, a marker of *SLC26A9* gene expression in CF phenotypes that show pre-natal onset (for example, meconium ileus). This may reflect that SLC26A9 and CFTR may act independently at this stage of development and is consistent with the observation that *Slc26a9* mRNA was high in the murine pancreas in the embryonic stages of development when *Cftr* was low (31). Given the small sample size, the rs7512462 association with lung function in individuals with two MF alleles requires further investigation and independent replication. However, a consistent beneficial effect of the CC rs7512462 genotype across several of our independent studies and disparate outcomes provides support that modulation of SLC26A9 can provide alternative chloride transport and could be a therapeutic target to improve lung function in individuals with any *CFTR* genotype. The modulation of alternative channels, transporters and pumps to compensate for dysfunctional CFTR (19, 77), and in particular SLC26A9 (9, 20, 31), would provide a mutation-agnostic approach and address the current unmet need of the CF individuals with MF alleles.

Given other published reports assessing the rs7512462 relationship with lung function in individuals with G551D variants (31, 32, 43), we used meta-analysis to summarize the current state of evidence. Together, the weight of evidence supports a relationship between the *SLC26A9* marker, rs7512462, and lung function in individuals with a G551D variant where there is cell-surface localized CFTR protein, but reduced activity. In an expanded CGMS cohort, we also replicated the enhancing effect of the rs7512462 C allele upon rescue of gating variants with IVA, suggesting that the pre-treatment effect may be reflective of constitutive activity and/or attributable to *SLC26A9*-aided residual CFTR function. Consistent with either is the suggestive association we observed between rs7512462 and lung function prior to treatment with LUM/IVA in individuals from the CGMS homozygous for Phe508del, with a reduced effect size possibly reflective of reduced cell membrane localization and interaction.

LUM/IVA was the first approved modulator for those homozygous for Phe508del, on the basis of reduced pulmonary exacerbations and lung function response. However, the average improvement in lung function in clinical trials (14) and observational studies (34) has been modest. To investigate whether the improvements in lung function from LUM/IVA are modified by the *rs7512462* genotype, we also genotyped the DNA from participants of the US observational LUM/IVA study, PROSPECT (<https://clinicaltrials.gov/ct2/show/NCT02477319>), and demonstrated that although modest in its average improvement in lung function, those with the CC rs7512462 genotype did exhibit the greatest benefit. Although this is the first report of *rs7512462* impact on clinical response, and in a real-world setting of treated patients, this finding is consistent with published studies of CFTR function in primary HBE and HNE cells from

individuals homozygous for Phe508del by us (31) and others (30), respectively. Together these findings across the two treated *CFTR* genotype groups replicate and expand previous reports (25, 26, 30, 31) that rs7512462 correlates with improved CFTR function.

We did evaluate CFTR function in nasal brushes from 36 individuals homozygous for Phe508del in Ussing chamber studies following 24h exposure to vehicle (DMSO), VX-770 with corrector VX-809 (corresponding to IVA/LUM) and a combination of VX-770, VX-809 and an experimental amplifier (68). We observed a similar trend to that reported in (30) with VX-809, although it did not reach statistical significance. When CFTR function was, however, augmented with the amplifier, the difference in CFTR function pre- and post-treatment was greatest in the cells with the rs7512462 CC genotype. These functional studies further support the hypothesis that SLC26A9 will likely benefit any therapeutic situation with increased apical surface localized CFTR protein, such as for the latest highly effective modulator treatment, ETI.

Although the population studies provide important insights into the relationship between CFTR and SLC26A9 marked by rs7512462 *in vivo*, functional studies in cellular and animal models will be necessary to understand the functional relationship between the two channels/transporters (78) and how they may be working together. The expression studies presented here provide guidance on the use of cellular models for SLC26A9 and further highlight potential limitations of cultured HNE for the unique considerations of studying SLC26A9 and CFTR that are distinct from the ones for studies of CFTR alone. Compared to naïve bronchial cells, we observed greater variation and lower expression in naïve nasal cells. Furthermore, the duration of culturing time of either HNE or HBE cells resulted in reduced *SLC26A9* expression. Presently,

the cultured HBE model appears superior to HNEs for investigations of *SLC26A9*, although further investigation of culturing conditions and of cell differentiation should to be considered.

Interestingly, the most significant *SLC26A9* locus SNPs from the CF GWAS (1, 7) also associate with lung function measurements in several large international studies: PEF and FEV₁/FVC ratio in participants from the UK Biobank aged 40-69 (9, 33); PEF and FEV₁/FVC ratio in the Spirometa consortium (33); and for the FEV₁/FVC ratio in 8-year-olds from the UK10K consortium (79). These results align with our findings that, after correction of CF-causal CFTR variants with modulators, *SLC26A9* locus SNPs are associated with improved lung function and CFTR function.

It is noteworthy that decreased spirometry is diagnostic for other obstructive lung diseases such as COPD (80). Several studies have reported similar pathobiology cascades between CF and COPD due to dysfunctional CFTR and environmental risk factors for COPD (81-85). For example, CFTR chloride channels show reduced capacity as a result of tobacco smoke and may result in the mucus obstruction characteristic of COPD (84, 86) that is akin to that seen in CF. If *SLC26A9* augments chloride transport, *SLC26A9* agonists could also be an effective therapeutic strategy for COPD. In support of this premise is the association evidence provided here demonstrating rs7512462 is a modifier of lung function in (33), with significant colocalization evidence between the CF and their UK Biobank + Spirometa Consortium summary statistics at the *SLC26A9* locus, reflective of a common underlying genetic contribution.

Conclusions

A role for SLC26A9 in the CF precision medicine landscape is an exciting prospect. SLC26A9 shows desirable characteristics (9) as an alternative therapeutic target for CF, including the urgent need for options for CF individuals with MF alleles. The association between rs7512462 genotype and response to existing pharmaceuticals indicate the potential to refine personalized combinations of modulators, and there is also support that SLC26A9 agonists may yield benefit to any existing pharmacological or gene correction paradigm in CF, independent of *CFTR* genotype. Further research should also address the potential for SLC26A9 agonists to improve measures of lung function in non-CF populations.

List of abbreviations

CF: cystic fibrosis; CFTR: cystic fibrosis transmembrane conductance regulator; IVA: Ivacaftor; LUM: lumacaftor; TZE: tezacaftor; ETI: elexacaftor and tezacaftor combined with ivacaftor; US: United States; GWAS: genome-wide association study; SLC26A9: Solute Carrier Family 26 member 9; GTEx: Genotype Tissue Expression project; eQTL: expression quantitative locus; HBE: human bronchial epithelia; COPD: chronic obstructive pulmonary disease; CGMS: Canadian CF Gene Modifier Study; HNE: human nasal epithelia; CFF: Cystic Fibrosis Foundation; CCFRD: Canadian CF Patient Data Registry; FEV₁: forced expiratory volume in one second; MF: minimal function; QC: quality control; FEV_{1pp}: forced expiratory volume in one second percent predicted; TPM: transcripts per million; PheWAS: Phenome-wide Association Study; PEF: peak expiratory flow; FVC: the forced vital capacity; FEV₁/FVC ratio: the ratio of forced expiratory volume in one second to the forced vital capacity; CCFRD: Canadian CF Patient Data Registry; Saknorm: the Survival adjusted average CF-specific Kulich FEV₁ percentiles that is normalized; QC: quality control; CFIT: CF Canada Sick Kids Program

723 in CF Individualized Therapy; P2: culture at Passage 2; P3: culture at Passage 3; LR: low risk;
 724 HR: high risk; PCs: principal components; TMM: trimmed mean of M values;
 725 PEER: *probabilistic estimation of expression residual* ; RIN: RNA integrity number; ERS/ATS:
 726 European Respiratory Society/American Thoracic Society.

727

728

729

Declarations

Ethics declarations

The Canadian Gene Modifier Study (CGMS) was approved by the Research Ethics Board of the Hospital for Sick Children (# 0020020214 from 2012-2019 and #1000065760 from 2019-present) and all participating sub-sites. Written informed consent was obtained from all participants or parents/guardians/substitute decision makers prior to inclusion in the study. The CGMS is approved by the Research Ethics Board of the Hospital for Sick Children for the usage of public and external data. The US PROSPECT study provides data from a clinical trial registered at clinicaltrials.gov, identifier NCT02477319, and we obtained these data through application to the US CFF at <https://www.cff.org/Research/Researcher-Resources/>.

Consents for publication

Not applicable.

Data Availability

The datasets generated and/or analyzed in this paper are publicly available. Data from the CGMS analyzed for the lung function pre- and post-modulator treatment are available from the Canadian CF registry at <https://www.cysticfibrosis.ca/our-programs/cf-registry/requesting-canadian-cf-registry-data>; the functional data and RNA-seq data from CGMS is available from the CFIT program at <https://lab.research.sickkids.ca/cfit/cystic-fibrosis-patients-families-researchers/>, and the paired cultured and fresh naïve HNE and HBE is available at GEO (GSE172232). The US PROSPECT data were obtained through application to the US CFF at <https://www.cff.org/Research/Researcher-Resources/> and the study is registered on <https://clinicaltrials.gov/ct2/show/NCT02477319>. The single-cell RNA-sequencing data are downloaded from the Human Lung Cell Atlas at <http://hlca.ds.czbiohug.org>. The summary

statistics for the pheWAS study is available at <https://atlas.ctglab.nl/PheWAS> and the meconium ileus association results that have been used for colocalization analysis can be downloaded at <https://lab.research.sickkids.ca/strug/publications-software/>. The data used for the COPD analysis are available through application to the UK Biobank.

Code availability

All code and analyses steps implemented to process the UK Biobank data are available at https://github.com/strug-hub/UKBB_spirometry_on_COPD. The software used for colocalization plotting and statistical testing is available at <https://locusfocus.research.sickkids.ca/>. The other analyses did not require any custom codes and are described in the Methods Section.

Competing interests

L.B. participated in a Vertex Virtual Advisory Board and she is a member of the CF Annual Faculty, sponsored by Vertex Pharmaceuticals. D.M-C. received an honorarium for teaching module development for Vertex Pharmaceuticals. N. M. is doing contract research trials for Vertex Pharmaceuticals and Abbvie. A.L.S has received speaking fees for educational programs sponsored by Vertex Pharmaceuticals. B.S.Q. has received speaker fees from Vertex Pharmaceuticals and has served as site PI for several Vertex-sponsored clinical trials. W.M.L is a study investigator for Vertex Pharmaceuticals. E.T., T.G. and F.R. act as a consultant for Vertex Pharmaceuticals. M.S. participated in Vertex clinical trials and received payment for education modules. J.G., G.H., C.W., C. Bartlett, N.P., S.M., F.L., K.K., J.A., A.H., M.S., M.E., G.C-M., D.A., S.B., C.Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., D.H., M.J.S., J.B., P.W., L.S., E.B., T.M., J.M.R and L.J.S. have no conflicts of interest.

Funding

Funding was provided by Cystic Fibrosis Foundation STRUG17PO, MORAES1610; Canadian Institutes of Health Research (FRN 167282), Cystic Fibrosis Canada (2626) and the CFIT Program funded by the SickKids Foundation and CF Canada; Natural Sciences and Engineering Research Council of Canada (RGPIN-2015- 03742, 250053-2013). This work was also funded by the Government of Canada through Genome Canada (OGI-148) and supported by a grant from the Government of Ontario. The funders of the study play no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions:

L.J.S conceptualized the study and the design. C. Bartlett, F.L., K.K., J.A., A.H., M. Shaw, M.E., G.C-M., D.A., S.B., C. Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., L.B., D.M-C., D.H., M.J.S., N.M., J.B., E.T., A.L.S., B.S.Q., P.W., W.M.L., M. Solomon, E.B., T.J.M., T.G., F.R. enrolled the participants and collected the biospecimens. J.G., G.H., C.W., N.P., S.M., L.J.S. carried out the statistical and bioinformatic analyses, created the visualizations and constructed the tables and Figures. L.S., T.G, J.M.R and L.J.S provided important insights to interpret the results and clarify the technical details for the methods, J.G., G.H., C.W., N.P., J.M.R., L.J.S. wrote the paper and all authors edited the paper. All authors have read and approved the final manuscript.

Acknowledgments

We thank the US CF Foundation for the use of Part B of the PROSPECT observational study. We thank the Cystic Fibrosis Canada–SickKids Program for Individualized Therapy for access to

the RNA-sequencing of the nasal epithelia. We thank the patients, care providers and clinic research assistants, collaborators, and principal investigators involved in CF Centers throughout Canada for their contributions to the CF Canada Patient Registry and Canadian Gene Modifier Study. Some of the research was conducted using the UK Biobank Resource under application Number 40946. We thank Shaf Keshavjee for providing the bronchial cells for paired analysis of gene expression and Hong Ouyang for culturing the epithelial cells. We thank Dr. John Miller for providing the amplifier for the study. The authors wish to acknowledge the staff supporting the High Performance Computing cluster and research helpdesk department and The Centre for Applied Genomics at the Hospital for Sick Children, Toronto.

References

1. Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, et al. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. *PLoS Genet.* 2019;15(2):e1008007.
2. Miller MR, Soave D, Li W, Gong J, Pace RG, Boëlle PY, et al. Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. *J Pediatr.* 2015;166(5):1152-7 e6.
3. Soave D, Miller MR, Keenan K, Li W, Gong J, Ip W, et al. Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study. *Diabetes.* 2014;63(6):2114-9.
4. Blackman S, Commander C, Watson C, Arcara K, Strug L, Stonebraker J, et al. Genetic modifiers of cystic fibrosis-related diabetes. *Diabetes.* 2013;62:3627-35.
5. Corvol H, Blackman SM, Boëlle PY, Gallins PJ, Pace RG, Stonebraker JR, et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. *Nat Commun.* 2015;6:8382.
6. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. *Nat Rev Genet.* 2015;16(1):45-56.
7. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. *Nat Genet.* 2012;44(5):562-9.
8. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. *Nat Genet.* 2013;45(10):1160-7.
9. Strug LJ, Stephenson AL, Panjwani N, Harris A. Recent advances in developing therapeutics for cystic fibrosis. *Hum Mol Genet.* 2018;27(R2):R173-R86.
10. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med.* 2011;365(18):1663-72.
11. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. *Nat Med.* 1996;2(4):467-9.
12. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *Lancet.* 2019;394(10212):1940-8.
13. Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J Med.* 2019;381(19):1809-19.
14. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. *N Engl J Med.* 2015;373(3):220-31.
15. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, Jr., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. *J Cyst Fibros.* 2012;11(3):237-45.
16. Haq IJ, Gray MA, Garnett JP, Ward C, Brodli M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. *Thorax.* 2016;71(3):284-7.

17. Martin SL, Saint-Criq V, Hwang TC, Csanady L. Ion channels as targets to treat cystic fibrosis lung disease. *J Cyst Fibros.* 2018;17(2S):S22-S7.
18. Balazs A, Mall MA. Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis. *Front Pharmacol.* 2018;9:1112.
19. Enterprise Therapeutics, editor Pharmacological characterisation of TMEM16A regulators. The 13th European Cystic Fibrosis Basic Science Conference; 2016; Pisa, Italy.
20. Mall MA, Galiotta LJ. Targeting ion channels in cystic fibrosis. *J Cyst Fibros.* 2015;14(5):561-70.
21. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. *Nature genetics.* 2015;47(8):856-60.
22. Aksit MA, Pace RG, Vecchio-Pagan B, Ling H, Rommens JM, Boelle PY, et al. Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits. *J Clin Endocrinol Metab.* 2020;105(5).
23. Lin YC, Keenan K, Gong J, Panjwani N, Avolio J, Lin F, et al. Cystic fibrosis-related diabetes onset can be predicted using biomarkers measured at birth. *Genet Med.* 2021;23(5):927-33.
24. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science.* 2020;369(6509):1318-30.
25. Bertrand CA, Mitra S, Mishra SK, Wang X, Zhao Y, Pilewski JM, et al. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9. *Am J Physiol Lung Cell Mol Physiol.* 2017;312(6):L912-L25.
26. Bertrand CA, Zhang R, Pilewski JM, Frizzell RA. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. *J Gen Physiol.* 2009;133(4):421-38.
27. Salomon JJ, Spahn S, Wang X, Fullekrug J, Bertrand CA, Mall MA. Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl⁻ channels. *Am J Physiol Lung Cell Mol Physiol.* 2016;ajplung 00321 2015.
28. Larsen MB, Choi JJ, Wang X, Myerburg MM, Frizzell RA, Bertrand CA. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia. *Am J Physiol Lung Cell Mol Physiol.* 2021;321(6):L1147-L60.
29. Liu X, Li T, Riederer B, Lenzen H, Ludolph L, Yeruva S, et al. Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO₃⁻ transport and reduces survival in CFTR-deficient mice. *Pflugers Arch.* 2015;467(6):1261-75.
30. Kmit A, Marson FAL, Pereira SV, Vinagre AM, Leite GS, Servidoni MF, et al. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients. *Biochim Biophys Acta Mol Basis Dis.* 2019;1865(6):1323-31.
31. Strug LJ, Gonska T, He G, Keenan K, Ip W, Boelle PY, et al. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. *Hum Mol Genet.* 2016;25(20):4590-600.
32. Corvol H, Mesinele J, Douksieh IH, Strug LJ, Boelle PY, Guillot L. SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis. *Front Pharmacol.* 2018;9:828.
33. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. *Nature genetics.* 2019;51(3):481-93.

34. Sagel SD, Khan U, Heltshe SL, Clancy JP, Borowitz D, Gelfond D, et al. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial. *Ann Am Thorac Soc*. 2021;18(1):75-83.
35. Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, Wright FA, et al. A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies. *Pediatr Pulmonol*. 2011;46(9):857-69.
36. Kim SO, Corey M, Stephenson AL, Strug LJ. Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries. *Thorax*. 2018;73(5):446-50.
37. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, et al. Disease-specific reference equations for lung function in patients with cystic fibrosis. *Am J Respir Crit Care Med*. 2005;172(7):885-91.
38. Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, et al. Modulators of CFTR. Updates on clinical development and future directions. *Eur J Med Chem*. 2021;213:113195.
39. Eckford PDW, McCormack J, Munsie L, He G, Stanojevic S, Pereira SL, et al. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF. *J Cyst Fibros*. 2019;18(1):35-43.
40. Travaglini KJ, Nabhan AN, Penland L, Sinha R, Gillich A, Sit RV, et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. *Nature*. 2020;587(7835):619-25.
41. Watanabe K, Stringer S, Frei O, Umicevic Mirkov M, de Leeuw C, Polderman TJC, et al. A global overview of pleiotropy and genetic architecture in complex traits. *Nature genetics*. 2019;51(9):1339-48.
42. Harrell FEJ. Regression Modeling Strategies With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. Cham: Springer; 2015.
43. Eastman AC, Pace RG, Dang H, Aksit MA, Vecchio-Pagan B, Lam AN, et al. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR. *J Cyst Fibros*. 2021.
44. Schwarzer G. metagen: Generic inverse variance meta-analysis. Preprint at <https://cran.r-project.org/web/packages/meta/meta.pdf>. 2021.
45. Viechtbauer W. metafor: Meta-Analysis Package for R. Preprint at <https://cran.r-project.org/web/packages/metafor/metafor.pdf>. 2020.
46. Gordon M, Lumley T. forestplot: Advanced Forest Plot Using 'grid' Graphics. Preprint at <https://cran.r-project.org/web/packages/forestplot/forestplot.pdf>. 2021.
47. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models using lme4. 2014.
48. Conomos MP. Population Structure and Relatedness Inference using the GENESIS Package 2021 [cited 2021 Feb-06].
49. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. *Genet Epidemiol*. 2015;39(4):276-93.
50. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship inference in genome-wide association studies. *Bioinformatics*. 2010;26(22):2867-73.
51. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet*. 2006;2(12):e190.

52. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. New York: Springer-Verlag; 2016.
53. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-9.
54. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779.
55. Band G, Marchini J. BGEN: a binary file format for imputed genotype and haplotype data. *bioRxiv*2018.
56. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet*. 2007;370(9589):765-73.
57. Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. *Bioinformatics*. 2017;33(17):2776-8.
58. McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating characteristics of the rank-based inverse normal transformation for quantitative trait analysis in genome-wide association studies. *Biometrics*. 2020;76(4):1262-72.
59. Panjwani N, Wang F, Mastromatteo S, Bao A, Wang C, He G, et al. LocusFocus: Web-based colocalization for the annotation and functional follow-up of GWAS. *PLoS Comput Biol*. 2020;16(10):e1008336.
60. Lam AN, Aksit MA, Vecchio-Pagan B, Shelton CA, Osorio DL, Anzmann AF, et al. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. *J Clin Invest*. 2020;130(1):272-86.
61. DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire MD, Williams C, et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. *Bioinformatics*. 2012;28(11):1530-2.
62. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol*. 2010;11(3):R25.
63. Ongen H, Buil A, Brown AA, Dermitzakis ET, Delaneau O. Fast and efficient QTL mapper for thousands of molecular phenotypes. *Bioinformatics*. 2016;32(10):1479-85.
64. Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nat Protoc*. 2012;7(3):500-7.
65. R Core Team. *R: A language and environment for statistical computing*. 2015.
66. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol*. 2018;19(1):15.
67. Jackman S, Tahk A, Zeileis A, Maimone C, Fearon J, Meers Z. *pscl: Political Science Computational Laboratory*. Preprint at <https://cran.r-project.org/web/packages/pscl/pscl.pdf>. 2020. 2020.
68. Giuliano KA, Wachi S, Drew L, Dukovski D, Green O, Bastos C, et al. Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors. *SLAS Discov*. 2018;23(2):111-21.
69. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science*. 2015;347(6220):1260419.

70. Eraslan G, Drokhlyansky E, Anand S, Subramanian A, Fiskin E, Slyper M, et al. Single-nucleus cross-tissue molecular reference maps to decipher disease gene function. Preprint at <https://www.biorxiv.org/content/10.1101/2021.07.19.452954v1>. 2021.
71. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science*. 2020;369(6509):1318-30.
72. Wang F, Panjwani N, Wang C, Sun L, Strug LJ. A flexible summary-based colocalization method with application to the mucin Cystic Fibrosis lung disease modifier locus. Accepted by. *AJHG*. 2021.
73. Stephens MB, Yew KS. Diagnosis of chronic obstructive pulmonary disease. *Am Fam Physician*. 2008;78(1):87-92.
74. Pinto MC, Quaresma MC, Silva IAL, Railean V, Ramalho SS, Amaral MD. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9. *Int J Mol Sci*. 2021;22(23).
75. Sato Y, Thomas DY, Hanrahan JW. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR. *J Biol Chem*. 2019;294(48):18269-84.
76. Fischer H. The G551D CFTR chloride channel spurs the development of personalized medicine. *J Physiol*. 2014;592(9):1907-8.
77. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. *Nature Reviews Disease Primers*. 2015;1:1-19.
78. Walter JD, Sawicka M, Dutzler R. Cryo-EM structures and functional characterization of murine Slc26a9 reveal mechanism of uncoupled chloride transport. *Elife*. 2019;8.
79. Baskurt Z, Mastromatteo S, Gong J, Wintle RF, Scherer SW, Strug LJ. VikNGS: a C++ variant integration kit for next generation sequencing association analysis. *Bioinformatics*. 2020;36(4):1283-5.
80. Johns DP, Walters JA, Walters EH. Diagnosis and early detection of COPD using spirometry. *J Thorac Dis*. 2014;6(11):1557-69.
81. Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. *Am J Respir Crit Care Med*. 2006;173(10):1139-44.
82. Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. *FASEB J*. 2012;26(2):533-45.
83. Raju SV, Jackson PL, Courville CA, McNicholas CM, Sloane PA, Sabbatini G, et al. Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. *Am J Respir Crit Care Med*. 2013;188(11):1321-30.
84. Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. *Chest*. 2013;144(2):498-506.
85. Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. *PLoS One*. 2012;7(6):e39809.
86. Mall MA. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc*. 2016;13 Suppl 2:S177-85.

Figures

Fig.1. Assessment of the association of rs7512462 in the Canadian CF Gene Modifier Study (CGMS) population broken down according to particular sub-study groups. Sample sizes indicated in parentheses represent the overlap with those published in (31). *This analysis is combined with the US PROSPECT cohort.

Fig. 2. Participant lung function or lung treatment response categorized by rs7512462 genotype.

(a) Boxplots of lung function from CGMS participants prior to modulator treatment, measured as Saknorm across different CFTR mutation groups. Saknorm is calculated as in (5, 35) with FEV₁ measurements taken prior to modulator treatment, if applicable. (b) Boxplot includes an overlay with a stripchart for treatment response in patients on IVA (n=45), LUM/IVA in PROSPECT cohort (n=91) or LUM/IVA in combined PROSPECT and CGMS samples (n=195). The center line, upper and lower box limits of boxplots correspond to the median, the third quartile (Q3) and the first quartiles (Q1), respectively; whiskers reflect the 1.5x interquartile range (IQR), i.e. bottom whisker is Q1-1.5xIQR and upper whisker is Q3 + 1.5 x IQR). Each dot represents an individual measurement. Following (31), the treatment response for IVA is defined as the difference between the mean post-treatment FEV_{1pp} within 15 to 400 days and FEV_{1pp} baseline.

1054 Response for LUM/IVA is defined as the difference in FEV_{1pp} between the first post treatment
1055 within 5 to 7 months to the baseline ((38); Methods).

1056

Fig.3. Boxplot overlaid with stripchart for CFTR function by rs7512462 genotype in HNE cultured to P2. The center line, upper and lower box limits of boxplots correspond to the median, the third quartile (Q3) and the first quartiles (Q1), respectively; whiskers reflect the 1.5x interquartile range (IQR), i.e. bottom whisker is $Q1 - 1.5 \times IQR$ and upper whisker is $Q3 + 1.5 \times IQR$. Each dot represents an individual measurement. The CFTR function is defined as the difference in ΔI_{eq} -forskolin from treatment with VX-770+VX-809 (left; n=36) or VX-770+VX-809+amplifier (right; n=30) to DMSO vehicle in CFTR-mediated current in cultured HNE from participants homozygous for Phe508del. More negative measurements reflect greater CFTR function.

Fig. 4. CFTR and SLC26A9 single-cell expression from the Human Lung Cell Atlas (40).

(a) Lung cell expression profiles from three individuals were clustered by nearest-neighbor and visualized using uniform manifold approximation and projection (UMAP). Normalized and log-scaled RNA counts for CFTR and SLC26A9 are plotted for each cell. Tissue compartment as defined by the Human Lung Cell Atlas is shown; expression of both CTFR and SLC26A9 is primarily restricted to epithelial cells; (b) UMAP clustering of epithelial lung cells only, cell types were annotated in the Human Lung Cell Atlas and (c) Breakdown of CFTR and SLC26A9 expression by cell type. Cells were grouped as having CFTR read count > 1 (red), SLC26A9 > 1 (blue) or co-expressing both (purple). Cell total varies and is annotated for each cell type.

Fig. 5. Lung function measures colocalize with CF meconium ileus GWAS at the *SLC26A9* locus. Visualization of colocalization using LocusFocus (59). Peak expiratory flow (PEF) association (n=345,265) from (33) is shown as circles with corresponding left y-axis against lines that trace (1) GTEx v7 adult lung eQTLs for *SLC26A9*; (2) meconium ileus GWAS (1); (3) FEV_{1pp} in UKBB participants (N=263,461; 22,071 of which have COPD as per GOLD level 2-4 definitions); (4) FEV1/FVC ratio from (33) (highest effective sample size is 396,686, a function of sample size (N=400,102) times imputation quality); and (5) Chronic obstructive pulmonary disease (COPD) case-control (22,071 cases and 241,390 controls). The choice of y-axis scales and primary dataset is for visualization purposes only and does not influence colocalization test result conclusions. There is a known gap on the human reference GRCh37 at chr1:205,922,708-206,072,707, which corresponds to the white gap in the figure as no variants exist. Lines traverse the lowest p-values per window as a visual guide (window size=6.67Kbp) with corresponding

right y-axis. A total of 85 SNPs in this region were used to test for colocalization using the Simple Sum method (1, 72). The Simple Sum colocalization test is implemented in the grey region, which was selected to match the observed peak at chr1:205,899,000-205,925,000. The color of the circles reflects the pairwise linkage disequilibrium (LD) with the rs7512462 lead SNP (purple) using the European subset of the 1000 Genomes Project, with varying strength of LD depicted with a different colour as denoted in the legend.

Tables

Table 1. Characteristics of participants included for response to CFTR modulators from the CGMS and US PROSPECT studies. The lung function measure used for the CFTR modulator study is forced expiratory volume in one second percent predicted (FEV_{1pp}). A subset of n=22 individuals from CGMS on IVA were included for analysis in (31) while n=23 are newly-recruited into the CGMS.

CGMS Participants in CFTR modulator study					US PROSPECT
Participants on CFTR modulator	Participant Characteristics	CGMS IVA (In (31), n=22 [*])	CGMS IVA (new, n=23)	CGMS LUM/IVA (n=104)	LUM/IVA (n=91)
rs7512462	TT/TC/CC	11/10/1	12/9/2	41/48/15	30/50/11
age	mean (range)	26.49 (6.1-58.3)	31.3 (14.0-55.3)	25.7 (10.5-55)	20.9 (6-57)
	age ≤ 12	5	0	2	23
	age (12,20]	4	3	38	27
	age (20,30]	3	11	38	24
	age>30	10	9	26	17
sex	female (%)	16 (72.7%)	13 (56.3%)	56 (53.8%)	52 (57.1%)
FEV_{1pp} baseline	mean (range)	66.6 (30.7-90.4)	58.9 (30.9-89.6)	59.6 (30.8-95.5)	75.7 (31.7-95.8)
Number of post-treatment FEV_{1pp} in 400 days	median (range)	4 (1-6)	4 (1-20)	6 (1-33)	4 (2-4)

^{*} one sample with FEV_{1pp} baseline outside the inclusion criteria and another who received a lung transplant were removed.

Table 2. Association between Saknorm and rs7512462 using additive and recessive codings in the CGMS cohort including individuals with a gating variant, individuals who are homozygous Phe508del or those who carry two MF alleles.

Models	Covariate	Effect size	S.E.	P-value
Additive	rs7512462_C	0.072	0.030	0.017
	CFTR-Gating/Other	0.210	0.094	0.025
	CFTR-MF/MF	-0.099	0.099	0.317
	Saknorm new reference equation	-0.244	0.050	1.41x10 ⁻⁶
Recessive	rs7512462_CC	0.130	0.057	0.022
	CFTR-Gating/Other	0.208	0.093	0.026
	CFTR-MF/MF	-0.101	0.099	0.307
	Saknorm new reference equation	-0.244	0.050	1.32x10 ⁻⁶

Saknorm is a continuous FEV₁- based CF-specific percentile that is normalized and accounts for age, sex and height and is survival adjusted (35). Saknorm is calculated as in (5, 37) with FEV₁ measurements taken prior to modulator treatment, if applicable. The combined samples include individuals with gating mutations (n=89), individuals homozygous for Phe508del (n=1,266) or those with two minimal function (MF) mutations (n=63). All analyses use the robust covariance matrix estimates by the R package ‘rms’ (42). In addition to rs7512462, both models include a *CFTR* mutation group indicator, with reference group as homozygous Phe508del. Saknorm new reference equation is an indicator for the reference equation used to calculate Saknorm (Methods) depending on the year the lung function measurement was taken.

Table 3. Association of rs7512462 for CFTR modulator response.

Studies	Covariates	Effect Size	S.E.	P-value
IVA(CGMS)	Age at baseline	-0.077	0.095	0.419
	FEV _{1pp} at baseline	-0.025	0.073	0.731
	rs7512462_CC	9.905	4.477	0.033
	Early CGMS Cohort	5.336	2.606	0.047
LUM/IVA (US PROSPECT)	Age at baseline	-0.188	0.074	0.014
	FEV _{1pp} at baseline	-0.123	0.053	0.024
	rs7512462_CC	8.518	2.657	0.002
LUM/IVA (US PROSPECT+CGMS)	Age at baseline	-0.119	0.064	0.066
	FEV _{1pp} at baseline	-0.069	0.037	0.066
	rs7512462_CC	5.217	1.871	0.006
	PROSPECT Cohort	0.865	1.401	0.540

CFTR modulator response is the difference between the FEV_{1pp} after the modulator response and the value at last visit before the treatment initiation within 3 months as defined in Methods. Increased Δ FEV_{1pp} indicates better treatment response. Sample sizes in each CFTR modulator treatment group are n=45 for IVA (CGMS), n=91 for LUM/IVA (US PROSPECT) and n=195 for the combined LUM/IVA analysis of the US PROSPECT and CGMS participants (US PROSPECT+CGMS). Early CGMS Cohort for IVA-CGMS reflects an indicator for those participants that were included in an earlier published study (31). LUM/IVA studies were also adjusted for population structure by PCs (n=7 PCs for US PROSPECT and n=4 for US PROSPECT+CGMS). PROSPECT Cohort is an indicator of whether the individual was a participant in the US PROSPECT study or the CGMS. All results use robust variance estimates.

Table 4. Association of rs7512462 for change of function to modulator treatment.

Studies	Covariates	Effect Size	S.E.	P-value
CFTR-mediated current (VX-770+VX-809)	rs7512462_CC	-0.406	0.417	0.3375
	Standard media	-1.969	0.456	0.0001
CFTR-mediated current (VX-770+VX-809+ amplifier)	rs7512462_CC	-1.934	0.572	0.0022
	Standard media	-2.170	0.697	0.0044

Forskolin-stimulated currents mediated by CFTR (measured as change in current after application of forskolin, ΔI_{eq} -forskolin) is used as the treatment response; more negative values correspond to more CFTR activity. Functional study includes HNEs from individuals homozygous for Phe508del with VX-770+VX-809 (n=36) and VX-770+VX-809+ amplifier (n=30; a subset of the 36 samples tested with 770+VX-809) measured as difference in CFTR-mediated current after applying forskolin regressed on rs7512462 with a recessive coding. All results use robust variance estimates.

Table 5: Co-expression between *SLC26A9* and *CFTR* using the Human Lung Atlas data (40).

Cell Type	Number of Cells	Zero-Inflated Negative Binomial Model			Spearman's Correlation	
		Effect Size	S.E.	P-Value	Rho	P-Value
Club	895	-0.00007	0.00125	0.9564	0.05173	0.12196
AT2*	760	0.00035	0.00013	0.0097	0.13215	0.00026
Basal	240	-11.65287	94.65422	0.9020	-0.02365	0.71544
AT1*	421	-8.41119	152.8630	0.9561	-0.01178	0.80962
AT2-s*	201	0.00143	0.00122	0.2433	0.28686	0.00004
Differentiating Basal	43	-0.02385	0.01931	0.2168	0.07235	0.64478
AT2 and AT2-s	961	0.00041	0.00014	0.0036	0.16567	< 0.00001
AT1, AT2 and AT2-s	1382	0.00048	0.00015	0.0018	0.32261	< 0.00001

The effect size estimate from zero-inflated negative binomial model indicates log-ratio relations between *CFTR* and *SLC26A9* expression. Values greater than zero correspond to positive co-expression. Spearman's correlation estimates (rho) were calculated using log-transformed read counts per million measures for *CFTR* and *SLC26A9*. The Spearman's correlation and the zero-inflated negative binomial model analysis were performed by R function `cor.test()` and package `pscl` (67), respectively. All p-values indicate two-sided statistical test results.

*: AT2: Alveolar Epithelial Type 2; AT1: Alveolar Epithelial Type 1; AT2-s: Signaling Alveolar Epithelial Type 2

Table 6. The 10 phenotypes with smallest rs7512462 association p-value obtained from the GWAS ATLAS (41).

PMID	Domain	Trait	Effect Size	P-value at rs7512462	N	Colocalization P-value
30804560	Respiratory	PEF (UKBB)	0.038	4.33×10^{-46}	321,047	2.24×10^{-9}
30804560	Respiratory	PEF (Meta of UKBB and Spirometa)	0.037	2.74×10^{-44}	345,265	2.82×10^{-8}
30807572	Gastrointestinal	Meconium ileus in CF	-0.289	1.86×10^{-9}	6,770	NA
28436984	Reproduction	Age at menarche	-0.021	3.93×10^{-6}	252,514	3.63×10^{-8}
30804560	Respiratory	FEV ₁ /FVC ratio (Meta of UKBB and Spirometa)	0.01	4.11×10^{-5}	400,102	6.03×10^{-9}
30804560	Respiratory	FEV ₁ /FVC ratio (UKBB)	0.01	1.44×10^{-4}	321,047	2.24×10^{-8}
23754948	Metabolic	Waist circumference (male)	0.03	2.2×10^{-4}	36,231	7.08×10^{-9}
25231870	Reproduction	Age at menarche	-0.023	3.2×10^{-4}	132,989	7.41×10^{-9}
19430480	Endocrine	Type 1 Diabetes	NA	7.47×10^{-4}	7,982	NA
23754948	Metabolic	Waist-hip ratio (male)	0.028	7.7×10^{-4}	34,629	1.78×10^{-8}

The colocalization p-value assesses evidence for common genetic contributions between the corresponding study phenotype and the meconium ileus CF GWAS (1) at chr1:205,895,000-205,921,000 locus. The effect allele in all studies is C, and the other allele is T, except for type 1 diabetes, where the effect size is not reported for the SNP in the original summary statistics from the listed publication (PMID). PheWAS significance level is $p < 1.05 \times 10^{-5}$ after adjusting for 4,756 GWAS in the database (alpha 0.05). UKBB refers to an analysis using the UK Biobank. ‘Colocalization P-value’ represents the p-values from the colocalization analysis calculated here with the CF GWAS summary statistics in (1) for the corresponding phenotype, using LocusFocus (59) calculated on the chr1: 205,895,000-205,925,000 region in hg19. NA in this column reflects a lack of information available to carry out the colocalization analysis.

Information about Supplementary Material

File name: Supplementary File_clean

File format: docx

Title of the data: Supplementary Information; Supplementary Result; Supplementary Figures and Supplementary Tables.

Description of the Data: This file includes the supplementary materials for the paper ‘**Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease**’

Supplementary Information includes the following subsections:

Sample Genotyping and Quality Control; High molecular weight DNA extraction methods;

Library preparation and 10x Genomics sequencing reads processing; Phasing imputed genotype

data using the 10XG multi-sample VCF file as the reference; HBE and HNE sampling;

Cell Culturing; Ussing chamber studies with primary human nasal epithelial cells; and

PheWAS data extraction and Colocalization with CF GWAS Summary Statistics.

Supplementary Result includes:

Haplotype association with Saknorm in CGMS participants homozygous for Phe508del

There are three figures in section **Supplementary Figures**:

Fig. S1. Forest plot of association between rs7512462 and lung function, measured as Saknorm (9) in individuals with at least one G551D variant.

Fig. S2. Forest plot of association between rs7512462 and lung function, measured as Saknorm (9) in individuals homozygous for Phe508del.

Fig. S3. SLC26A9 gene expression in various tissue models to guide functional studies.

There are four tables in section **Supplementary Tables**:

Supplementary Table 1: Number of participants removed according to the exclusion criteria for the CFTR modulator study.

Supplementary Table 2: Meta-analysis for the association between rs7512462 and lung function prior to treatment with Ivacaftor.

Supplementary Table 3: Haplotype association with Saknorm in individuals in the CGMS who are homozygous Phe508del.

Supplementary Table 4: Association analysis using a linear mixed model with a random intercept with n=45 individuals on ivacaftor with multiple follow-up measures within [15,400] days.